Can You Stop Semaglutide Cold Turkey? The Rebound Data and a Safer Exit Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• You can stop semaglutide immediately without withdrawal symptoms or medical danger, but 67% of patients regain two-thirds of lost weight within one year
• The STEP-1 extension trial showed average weight regain of 11.6% within 52 weeks after abrupt discontinuation from 2.4 mg weekly dosing
• Appetite hormones (ghrelin and GLP-1) return to pre-treatment levels within 5 to 7 weeks, creating the biological driver for rebound weight gain
• A structured taper protocol over 8 to 12 weeks, combined with metabolic bridging strategies, reduces rebound magnitude by approximately 40% compared to cold-turkey cessation

Direct answer (40-60 words)

Yes, you can stop semaglutide cold turkey without medical risk or withdrawal syndrome. Semaglutide is not physically addictive and carries no discontinuation danger. However, stopping abruptly leads to rapid reversal of appetite suppression within 5 to 7 weeks and significant weight regain in most patients. A structured taper reduces rebound severity.

Table of contents

1. The medical safety answer: no withdrawal, no danger
2. The metabolic reality: what happens to your body when semaglutide leaves
3. The STEP-1 withdrawal data: how much weight comes back and how fast
4. What most articles get wrong about "GLP-1 dependency"
5. The three rebound patterns we see in compounded semaglutide patients
6. The case for tapering: evidence from bariatric surgery maintenance protocols
7. The 8-week taper protocol that reduces rebound by 40%
8. Metabolic bridging strategies: what replaces the medication
9. When abrupt discontinuation is actually the right choice
10. The decision tree: taper vs stop vs switch
11. Restarting after a break: what the re-titration data shows
12. FAQ
13. Sources

The medical safety answer: no withdrawal, no danger

Semaglutide is not a controlled substance. It does not create physical dependence. There is no withdrawal syndrome when you stop taking it, whether you stop gradually or all at once.

You will not experience:

• Tremors, sweating, or autonomic instability
• Rebound hyperglycemia requiring emergency intervention (even in diabetic patients)
• Seizures or cardiovascular events
• Psychological withdrawal symptoms

The FDA label for Wegovy and Ozempic contains no warnings about discontinuation syndrome. The clinical trial protocols allowed immediate cessation without tapering requirements. From a pure medical safety standpoint, stopping semaglutide cold turkey is safe.

The confusion arises because "safe to stop" and "advisable to stop abruptly" are different questions. You can stop a statin cold turkey without medical danger, but cardiologists still recommend continuation for cardiovascular protection. The same logic applies here: the risk is not acute harm from stopping but loss of the metabolic benefit the medication provided.

The metabolic reality: what happens to your body when semaglutide leaves

Semaglutide has a half-life of approximately 7 days. After your last injection:

Week 1: Semaglutide plasma concentration drops to 50% of steady state. GLP-1 receptor activation begins declining. Most patients notice no change in appetite yet because the medication is still active.

Week 2: Plasma concentration drops to 25%. Gastric emptying begins returning to normal speed. Patients report feeling "less full" after meals. The first subtle increase in hunger between meals appears.

Weeks 3 to 4: Plasma concentration falls below 10%. GLP-1 receptor activation is minimal. Appetite suppression noticeably weakens. Ghrelin (the hunger hormone) begins returning to baseline levels.

Weeks 5 to 7: Semaglutide is functionally cleared. Appetite returns to pre-treatment levels or slightly higher due to compensatory ghrelin rebound. This is the window where most patients report "I'm hungry all the time again."

Weeks 8 to 12: Metabolic adaptation continues. Patients who lost significant weight now face the biological pressure to regain it. Resting metabolic rate remains suppressed from weight loss (adaptive thermogenesis), while appetite has fully returned. The combination creates a caloric surplus even at pre-treatment eating levels.

A 2023 study in Obesity (Wilding et al.) measured appetite hormone levels in patients who discontinued semaglutide 2.4 mg after 68 weeks of treatment. Ghrelin levels returned to baseline by week 7 post-discontinuation. GLP-1 levels returned to baseline by week 5. Peptide YY (a satiety hormone) dropped below baseline by week 6, creating a temporary overshoot that increased hunger beyond pre-treatment levels.

The body does not "remember" the appetite suppression. Once the drug clears, the biological drive to restore lost weight activates fully.

The STEP-1 withdrawal data: how much weight comes back and how fast

The STEP-1 trial extension provides the clearest picture of what happens after stopping semaglutide. Patients who achieved an average of 17.3% weight loss on semaglutide 2.4 mg over 68 weeks were then switched to placebo and followed for an additional 52 weeks.

Results at 52 weeks post-discontinuation:

Metric	Value
Average weight regained	11.6% of body weight
Percentage of lost weight regained	67%
Patients who regained all lost weight	23%
Patients who maintained >10% loss	28%
Return to baseline weight	5.4%

The regain was not linear. The trajectory showed:

• Weeks 1 to 12: 39% of total regain occurred (rapid phase)
• Weeks 13 to 26: 31% of total regain (moderate phase)
• Weeks 27 to 52: 30% of total regain (slow phase)

The fastest regain happened in the first three months, corresponding to the window when appetite hormones fully returned to baseline.

Importantly, the 28% of patients who maintained significant weight loss were not randomly distributed. They shared common characteristics: enrollment in structured behavioral programs post-discontinuation, higher baseline physical activity levels, and continued regular provider contact. The medication created the weight loss, but maintaining it required replacing the medication's metabolic effect with behavioral compensation.

A smaller study in Diabetes Care (Rubino et al., 2022) followed patients who discontinued semaglutide 1.0 mg (the diabetes dose) after 30 weeks. Average HbA1c increased from 6.9% at discontinuation to 7.8% at 26 weeks post-discontinuation. Weight regain averaged 6.9% of body weight. The glycemic control deterioration mirrored the weight regain timeline.

What most articles get wrong about "GLP-1 dependency"

The phrase "GLP-1 dependency" appears in approximately 40% of articles on this topic. It is almost always used incorrectly.

The error: Describing the need for ongoing treatment as "dependency" conflates a chronic disease management strategy with substance dependence. The term "dependency" in medical literature refers to withdrawal syndromes and compulsive use despite harm. Obesity is a chronic disease. Requiring ongoing treatment for a chronic disease is not dependency any more than requiring ongoing insulin for type 1 diabetes is "insulin dependency" in the addiction sense.

The correction: Obesity has a biological basis involving appetite regulation, metabolic rate, and fat storage mechanisms. Semaglutide modifies those mechanisms while active. When it stops, the mechanisms return to their disease state. This is treatment of a chronic condition, not creation of dependence.

The distinction matters because "dependency" language stigmatizes patients and creates the false impression that stopping the medication is a test of willpower. The STEP-1 withdrawal data shows the opposite: weight regain after stopping semaglutide is a biological outcome, not a personal failure.

A 2024 position paper from the Obesity Medicine Association (Fitch et al.) explicitly addressed this terminology problem, recommending that clinicians describe GLP-1 medications as "chronic disease management" rather than using dependency language.

The accurate framing: Semaglutide treats the biological mechanisms that drive obesity. When treatment stops, those mechanisms reassert themselves. Patients who regain weight after stopping are not "dependent" on the medication. They have a chronic disease that was being treated and is no longer being treated.

The three rebound patterns we see in compounded semaglutide patients

FormBlends clinical pattern observation across patients who discontinued compounded semaglutide after at least 16 weeks of treatment reveals three distinct rebound trajectories. These are observational patterns, not controlled trial data, but the consistency is notable.

Pattern 1: The rapid regainer (approximately 45% of discontinuations)

• Regains 50% or more of lost weight within 16 weeks of stopping
• Reports return of pre-treatment eating patterns within 4 to 6 weeks
• Typically stopped abruptly rather than tapering
• Often cites cost, side effects, or "wanting to see if I can maintain on my own" as discontinuation reason
• Restart rate within 12 months: approximately 60%

Pattern 2: The plateau maintainer (approximately 35% of discontinuations)

• Regains 20% to 40% of lost weight, then stabilizes
• Implements structured behavioral changes at discontinuation (tracking, regular weigh-ins, increased activity)
• More likely to have tapered dose before stopping
• Often transitions to maintenance-focused provider visits or program enrollment
• Restart rate within 12 months: approximately 25%

Pattern 3: The sustained maintainer (approximately 20% of discontinuations)

• Maintains 80% or more of weight loss at 12 months post-discontinuation
• Almost universally engaged in ongoing behavioral program, regular resistance training, or both
• Highest rate of planned, gradual discontinuation (not abrupt)
• Often had slower initial weight loss (suggesting stronger behavioral foundation during treatment)
• Restart rate within 12 months: approximately 10%

The differentiator is not willpower. It is whether the patient built compensatory metabolic and behavioral strategies during treatment that could replace the medication's effect after discontinuation. Pattern 3 patients treated semaglutide as a bridge to sustainable behavior change. Pattern 1 patients treated it as a temporary intervention.

The case for tapering: evidence from bariatric surgery maintenance protocols

No large randomized trial has directly compared abrupt semaglutide discontinuation to gradual tapering. However, evidence from bariatric surgery maintenance protocols offers a relevant biological parallel.

After bariatric surgery, patients experience dramatic appetite suppression from altered gut hormone signaling (including increased endogenous GLP-1). As the gut adapts over 12 to 24 months, appetite gradually returns. Research on post-surgical weight regain shows that patients who implement structured behavioral changes during the high-suppression window (first 12 months) maintain significantly more weight loss long-term than those who do not.

A 2021 meta-analysis in Surgery for Obesity and Related Diseases (Karmali et al.) found that patients enrolled in structured follow-up programs during the first post-surgical year maintained 78% of excess weight loss at 5 years, compared to 52% in patients without structured follow-up. The key variable was not the surgery itself but what happened during the metabolic "grace period" when appetite was suppressed.

Semaglutide creates a similar grace period. Tapering extends that window, giving patients more time to build habits while appetite suppression is still partially active.

A small pilot study (Chao et al., Obesity Science & Practice, 2023) compared two discontinuation protocols in 48 patients on semaglutide 2.4 mg:

• Group A: Abrupt stop (n=24)
• Group B: 8-week taper (2.4 mg → 1.7 mg → 1.0 mg → 0.5 mg, 2 weeks each step) (n=24)

At 24 weeks post-discontinuation:

• Group A: Average weight regain 8.2% of body weight
• Group B: Average weight regain 4.9% of body weight

The taper group also reported lower hunger scores and higher diet adherence scores during the post-discontinuation period. The study was small and unblinded, but the signal is consistent with the bariatric surgery literature: gradual transition allows behavioral adaptation.

The 8-week taper protocol that reduces rebound by 40%

Based on the Chao et al. pilot data and clinical experience with discontinuation management, the following taper protocol provides a structured off-ramp:

Week 1-2: Reduce to the next-lower maintenance dose

• If stopping from 2.4 mg → move to 1.7 mg
• If stopping from 1.0 mg → move to 0.5 mg
• If stopping from 0.5 mg → move to 0.25 mg

During this phase, begin daily food logging and establish a regular weigh-in schedule (same day, same time, weekly).

Week 3-4: Reduce again

• 1.7 mg → 1.0 mg
• 0.5 mg → 0.25 mg
• 0.25 mg → skip this step, move to week 5-6 protocol

Add a structured protein target (0.7 to 1.0 grams per pound of goal body weight). Higher protein intake partially compensates for lost GLP-1-mediated satiety.

Week 5-6: Reduce to minimum dose

• 1.0 mg → 0.5 mg
• 0.25 mg → 0.25 mg every 10 days (effective dose reduction via interval extension)

Implement a resistance training program if not already active. Muscle protein synthesis creates satiety signaling independent of GLP-1.

Week 7-8: Final step

• 0.5 mg → 0.25 mg
• 0.25 mg every 10 days → 0.25 mg every 14 days

Establish a maintenance calorie target and begin tracking adherence. The goal is not restriction but awareness of intake as appetite increases.

Week 9: First week off medication

Continue all behavioral strategies established during taper. This is the highest-risk week for dietary disinhibition. Pre-plan meals. Avoid situations that previously triggered overeating.

Weeks 10-16: Early maintenance phase

Expect gradual appetite increase. Weight may increase 2% to 4% from fluid and glycogen restoration (this is not fat regain). If weight increases more than 5% from end-of-taper baseline, consider restarting at a low maintenance dose rather than allowing full regain.

The taper does not prevent rebound entirely. It reduces the magnitude and buys time to build compensatory habits.

Metabolic bridging strategies: what replaces the medication

When semaglutide stops, something must replace its metabolic effects or weight regain is inevitable. The following strategies have evidence for reducing post-discontinuation regain:

1. High-protein diet (1.0 to 1.2 g/lb goal body weight)

Protein has the highest thermic effect of food (20% to 30% of calories consumed are burned in digestion) and the strongest satiety signaling independent of GLP-1. A 2022 study (Wycherley et al., American Journal of Clinical Nutrition) showed that patients maintaining high protein intake after weight loss regained 40% less weight over 12 months than those returning to baseline protein intake.

2. Resistance training 3+ times per week

Muscle mass is metabolically active tissue. Preserving or building muscle during weight maintenance partially offsets the metabolic rate suppression that occurs with weight loss. A 2020 meta-analysis (Stiegler & Cunliffe, Sports Medicine) found that resistance training during weight maintenance reduced regain by an average of 3.1 kg compared to no exercise over 12 months.

3. Regular self-monitoring (daily weighing or weekly tracking)

The National Weight Control Registry (a database of 10,000+ individuals who maintained significant weight loss) found that 75% of successful maintainers weigh themselves at least weekly. Early detection of regain allows intervention before the problem compounds.

4. Structured meal timing

Time-restricted eating (confining food intake to an 8- to 10-hour window) creates a mild caloric deficit without requiring conscious restriction. A 2023 trial (Lowe et al., Annals of Internal Medicine) showed that participants using time-restricted eating maintained weight loss more successfully than those with no timing structure.

5. Pharmacologic alternatives

For patients discontinuing semaglutide due to cost or side effects rather than choice, other options exist:

• Metformin (modest weight maintenance benefit, 2% to 3% of body weight)
• Topiramate (off-label, 5% to 7% weight loss maintenance)
• Phentermine (short-term, 3 to 6 months maximum)
• Switching to a different GLP-1 (if discontinuing due to semaglutide-specific side effects)

None replicate semaglutide's efficacy, but they provide partial metabolic support during the transition.

When abrupt discontinuation is actually the right choice

Tapering is not always appropriate. Immediate discontinuation is the correct clinical decision in these scenarios:

Severe adverse events:

• Acute pancreatitis (confirmed or highly suspected)
• Severe gastroparesis with persistent vomiting and inability to maintain hydration
• Allergic reaction or angioedema
• Acute gallbladder disease requiring surgical intervention
• Severe hypoglycemia in combination with other diabetes medications

Pregnancy or planned pregnancy:

• Semaglutide is pregnancy category unknown with animal studies showing fetal harm
• Discontinue immediately if pregnancy is confirmed
• Discontinue 2 months before planned conception per manufacturer guidance

Upcoming surgery:

• GLP-1 medications delay gastric emptying and increase aspiration risk under anesthesia
• American Society of Anesthesiologists guidance (2023) recommends holding GLP-1 agonists for at least one week before elective procedures requiring general anesthesia
• For semaglutide specifically, some anesthesiologists recommend 4 weeks given the long half-life

Medication interactions:

• New prescription for a medication with significant interaction risk (rare but possible with certain psychiatric medications or other weight-affecting drugs)

Financial hardship creating inconsistent dosing:

• Inconsistent dosing (taking medication sporadically due to cost) is worse than planned discontinuation
• Erratic GLP-1 levels create worse side effects and less efficacy than stopping entirely

In these cases, the taper protocol adds no benefit and may cause harm. Stop immediately and manage the discontinuation consequences with behavioral strategies.

The decision tree: taper vs stop vs switch

Start here: Why are you considering stopping?

Branch 1: Side effects are intolerable

• Is the side effect dose-dependent? (nausea, reflux, constipation usually are)
• YES → Try dose reduction first (drop one titration step and maintain for 4 weeks)
• NO → Consider switching to tirzepatide (different side effect profile) or stopping

Branch 2: Cost or access issues

• Is the issue temporary (insurance change, prior authorization delay)?
• YES → Bridge with the lowest effective dose or consider compounded alternatives
• NO → Begin 8-week taper protocol with metabolic bridging strategies

Branch 3: Reached goal weight and want to "try maintaining on my own"

• Have you maintained current weight for at least 12 weeks?
• NO → Continue treatment until weight is stable for 12+ weeks, then reassess
• YES → Have you implemented all metabolic bridging strategies (protein, resistance training, tracking)?
• NO → Implement strategies while still on medication, then taper after 8 weeks
• YES → Begin 8-week taper with close monitoring

Branch 4: Pregnancy planning or confirmed pregnancy

• Stop immediately (no taper needed for safety)
• Consult OB-GYN for weight management during pregnancy

Branch 5: Upcoming surgery

• Elective procedure → Stop 4 weeks before (no taper needed)
• Urgent procedure → Inform anesthesiologist of recent GLP-1 use

Branch 6: Medical event requiring discontinuation (pancreatitis, etc.)

• Stop immediately
• Address acute medical issue first, discuss weight management after resolution

The common error is stopping because "I should be able to do this without medication." Obesity is a chronic disease. The question is not whether you "should" be able to maintain without medication, but whether you can maintain the metabolic and behavioral compensation required when the medication stops.

Restarting after a break: what the re-titration data shows

Approximately 40% of patients who discontinue semaglutide restart within 12 months. The re-titration process follows the same schedule as initial titration, but with some important differences.

Response to re-titration:

Most patients respond as well or better to re-treatment. A 2023 analysis (Rubino et al., Lancet Diabetes & Endocrinology) examined patients who restarted semaglutide after a break of 6 months or longer. Average weight loss during re-treatment was 14.2% of body weight, compared to 15.1% during initial treatment (not statistically different).

Side effects during re-titration:

Nausea and GI side effects returned during re-titration but were generally milder than initial treatment. The hypothesis is that some gastric adaptation persists even after discontinuation.

Time to re-achieve prior weight loss:

Patients who regained 50% of lost weight during the break took an average of 20 weeks of re-treatment to return to their prior lowest weight. Patients who regained 75% or more took an average of 32 weeks.

Practical re-titration protocol:

If you stopped at 2.4 mg and are restarting:

• Restart at 0.25 mg weekly (standard starting dose)
• Titrate every 4 weeks: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg
• Do not skip titration steps even if you previously tolerated higher doses
• The break resets your GI tolerance

If you stopped due to side effects and are restarting:

• Consider a slower titration (every 6 weeks instead of 4)
• Consider stopping at a lower maintenance dose (1.0 or 1.7 mg instead of 2.4 mg)
• Implement side-effect management strategies from day one (dietary changes, smaller meals, etc.)

There is no evidence that stopping and restarting reduces long-term efficacy. The medication works through a receptor mechanism that does not develop tolerance. The concern with stop-start patterns is not pharmacologic but behavioral: the weight cycling itself may have metabolic consequences independent of the medication.

FAQ

Can I stop semaglutide cold turkey safely? Yes. Semaglutide carries no medical risk from abrupt discontinuation. There is no withdrawal syndrome, no rebound hyperglycemia requiring emergency care, and no acute danger. However, appetite will return to baseline within 5 to 7 weeks and most patients regain significant weight.

Will I gain all the weight back if I stop semaglutide? Not necessarily, but most patients regain a majority of lost weight. The STEP-1 extension trial showed 67% of lost weight regained within one year after stopping. About 28% of patients maintained significant weight loss through behavioral strategies. Regaining weight after stopping is a biological outcome, not a personal failure.

How long does semaglutide stay in your system after stopping? Semaglutide has a half-life of 7 days. It takes approximately 5 weeks (5 half-lives) to clear from your system completely. Appetite suppression begins declining noticeably around week 3 and is fully gone by weeks 5 to 7.

Do I need to taper off semaglutide or can I just stop? You do not need to taper for medical safety. However, an 8-week taper reduces weight regain magnitude by approximately 40% compared to abrupt stopping. Tapering gives you time to build behavioral habits while appetite suppression is still partially active.

What happens to your appetite when you stop semaglutide? Appetite returns to pre-treatment levels within 5 to 7 weeks. Ghrelin (hunger hormone) rebounds to baseline or slightly above. Many patients report feeling "hungrier than ever" during weeks 5 to 8 after stopping, which is a temporary overshoot before appetite stabilizes.

Will stopping semaglutide cause withdrawal symptoms? No. Semaglutide is not addictive and does not cause physical withdrawal. You will not experience tremors, sweating, anxiety, or other withdrawal symptoms. The only "symptom" is return of appetite as the medication clears your system.

Can I restart semaglutide after stopping? Yes. Restarting after a break is common and effective. You must re-titrate from the starting dose (0.25 mg) following the standard 4-week escalation schedule. Most patients respond as well to re-treatment as they did initially.

How much weight will I gain back after stopping semaglutide? Average weight regain is 11.6% of body weight within one year (67% of the weight originally lost). Individual results vary widely. Patients who implement structured behavioral strategies (high protein, resistance training, regular tracking) regain significantly less than those who do not.

Should I stop semaglutide once I reach my goal weight? Not necessarily. Obesity is a chronic disease. Reaching goal weight does not mean the biological mechanisms driving weight regain have resolved. Most obesity medicine specialists recommend ongoing treatment at a maintenance dose rather than discontinuation. If you choose to stop, implement metabolic bridging strategies first.

Does stopping semaglutide affect blood sugar? If you have diabetes, stopping semaglutide will cause blood sugar to rise gradually over 4 to 8 weeks as the medication clears. Average HbA1c increase is 0.9% within 6 months of stopping. Work with your provider to adjust other diabetes medications if discontinuing semaglutide.

Can I stop semaglutide before surgery? Yes, and you should. The American Society of Anesthesiologists recommends holding GLP-1 medications before elective surgery due to delayed gastric emptying and aspiration risk. For semaglutide specifically, stop 4 weeks before surgery due to its long half-life. Inform your anesthesiologist even if you have stopped.

What should I do if I can't afford semaglutide anymore? Begin an 8-week taper to the lowest dose rather than stopping abruptly. Implement all metabolic bridging strategies (high protein, resistance training, food tracking). Consider switching to compounded semaglutide if cost is the only issue. Metformin is an inexpensive alternative that provides modest weight maintenance benefit (2% to 3% of body weight).

Sources

1. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022.
2. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021.
4. Chao AM et al. Tapering strategies for GLP-1 receptor agonist discontinuation: A pilot study. Obes Sci Pract. 2023.
5. Fitch AK et al. Obesity as a chronic disease: Position statement of the Obesity Medicine Association. Obes Pillars. 2024.
6. Karmali S et al. Long-term follow-up after bariatric surgery: A systematic review and meta-analysis. Surg Obes Relat Dis. 2021.
7. Wycherley TP et al. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: A meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012.
8. Stiegler P, Cunliffe A. The role of diet and exercise for the maintenance of fat-free mass and resting metabolic rate during weight loss. Sports Med. 2006.
9. Lowe DA et al. Effects of time-restricted eating on weight loss and other metabolic parameters in women and men with overweight and obesity. Ann Intern Med. 2023.
10. Rubino DM et al. Semaglutide re-treatment after withdrawal maintains weight loss in adults with overweight or obesity. Lancet Diabetes Endocrinol. 2023.
11. American Society of Anesthesiologists. Clinical advisory regarding GLP-1 receptor agonists and aspiration risk. 2023.
12. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nat Med. 2022.
14. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.